Zometa®
ZOMETA is indicated for the prevention of SREs* in patients with advanced malignancies involving bone.
*SRE=skeletal-related event—defined as pathological fracture, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.
This information is based on the European Summary of Product Characteristics. The prescribing information in your country may vary; please consult your local prescribing information and/or contact your local Novartis representative.
www.zometa.com »
(For Non U.S. Health Care Professionals Only)
www.us.zometa.com/health-care-professional/patient-treatment.jsp »
(For U.S. Health Care Professionals Only)
www.us.zometa.com »
(For U.S. Residents Only)